Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Chinese Journal of cardiovascular Rehabilitation Medicine ; (6): 154-157, 2018.
Artículo en Chino | WPRIM | ID: wpr-699370

RESUMEN

Objective:To explore therapeutic effects of rosuvastatin and atorvastatin on patients with coronary heart disease(CHD)angina pectoris and their influence on blood lipids.Methods:A total of 100 CHD inpatients with sta-ble angina pectoris(SAP)were selected.According to random control table,they were randomly and equally divid-ed into rosuvastatin group and atorvastatin group.Both groups received corresponding lipid-lowering medication based on routine treatment of CHD angina pectoris for four weeks.Clinical and ECG therapeutic effect were ob-served,blood lipid levels were measured before and after treatment,adverse drug reactions were observed and medi-ation cost was recorded in two groups.Results:Compared with atorvastatin group,there were significant rise in clinical and ECG total effective rate[(76% vs.92%),(60% vs.84%)],and significant reduction in mediation cost[(12369.94 ± 231.81)RMB vs.(11784.52 ± 206.97)RMB]in rosuvastatin group,P<0.05 or <0.01. There were no significant difference in blood lipid levels between two groups before and after treatment(P>0.05 all),and all of them were inside normal range.There was no significant difference in incidence rate of adverse drug reactions between two groups(P>0.05).Conclusion:Compared with atorvastatin,rosuvastatin can more significantly prevent onset of CHD angina pectoris, and it's safe,effective,and hospitalization cost is significantly reduction.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA